These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12615451)

  • 1. Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques.
    Tobery TW; Smith JF; Kuklin N; Skulsky D; Ackerson C; Huang L; Chen L; Cook JC; McClements WL; Jansen KU
    Vaccine; 2003 Mar; 21(13-14):1539-47. PubMed ID: 12615451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.
    Yan X; Wang D; Liang F; Fu L; Guo C
    Hum Vaccin Immunother; 2014; 10(12):3491-8. PubMed ID: 25483698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
    Park JS; Oh YK; Kang MJ; Kim CK
    J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes.
    Dupuy C; Buzoni-Gatel D; Touzé A; Bout D; Coursaget P
    J Virol; 1999 Nov; 73(11):9063-71. PubMed ID: 10516012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
    J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.
    Giannini SL; Hanon E; Moris P; Van Mechelen M; Morel S; Dessy F; Fourneau MA; Colau B; Suzich J; Losonksy G; Martin MT; Dubin G; Wettendorff MA
    Vaccine; 2006 Aug; 24(33-34):5937-49. PubMed ID: 16828940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Humoral immune response and in vitro neutralizing antibody assay on co-delivery of protein HPV16L1 virus-like particle with HPV16L1 gene].
    Song JM; Sun XL; Wang YL; Guo JF; Liu TJ; Si LS
    Zhonghua Bing Li Xue Za Zhi; 2005 Jul; 34(7):421-4. PubMed ID: 16251048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Papillomavirus-like particle vaccines.
    Schiller JT; Lowy DR
    J Natl Cancer Inst Monogr; 2001; (28):50-4. PubMed ID: 11158207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.
    Baud D; Ponci F; Bobst M; De Grandi P; Nardelli-Haefliger D
    J Virol; 2004 Dec; 78(23):12901-9. PubMed ID: 15542642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine.
    Emeny RT; Wheeler CM; Jansen KU; Hunt WC; Fu TM; Smith JF; MacMullen S; Esser MT; Paliard X
    J Virol; 2002 Aug; 76(15):7832-42. PubMed ID: 12097595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques.
    Feng Y; Li C; Hu P; Wang Q; Zheng X; Zhao Y; Shi Y; Yang S; Yi C; Feng Y; Wu C; Qu L; Xu W; Li Y; Sun C; Gao FG; Xia X; Feng L; Chen L
    Emerg Microbes Infect; 2018 Jun; 7(1):101. PubMed ID: 29872043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
    Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques.
    Dale CJ; Liu XS; De Rose R; Purcell DF; Anderson J; Xu Y; Leggatt GR; Frazer IH; Kent SJ
    Virology; 2002 Sep; 301(1):176-87. PubMed ID: 12359458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
    Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
    J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
    Da Silva DM; Pastrana DV; Schiller JT; Kast WM
    Virology; 2001 Nov; 290(2):350-60. PubMed ID: 11883199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.
    Latimer B; Toporovski R; Yan J; Pankhong P; Morrow MP; Khan AS; Sardesai NY; Welles SL; Jacobson JM; Weiner DB; Kutzler MA
    Hum Vaccin Immunother; 2014; 10(8):2357-65. PubMed ID: 25424943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine.
    Gupta G; Giannino V; Rishi N; Glueck R
    Vaccine; 2016 Sep; 34(39):4724-4731. PubMed ID: 27523740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants.
    Cho HJ; Kim JY; Lee Y; Kim JM; Kim YB; Chun T; Oh YK
    Vaccine; 2010 Mar; 28(14):2598-606. PubMed ID: 20116467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
    Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
    Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.